IMMUNOCORE HLDGS ADS/1 Total Assets
IMMUNOCORE HLDGS ADS/1 total assets. Based on the latest financial reports, IMMUNOCORE HLDGS ADS/1 (6YG) holds total assets worth €1.12 Billion EUR (≈ $1.31 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 6YG market cap overview for the company's overall valuation and market capitalisation.
Total Assets of IMMUNOCORE HLDGS ADS/1 (2022–2025)
Total assets of IMMUNOCORE HLDGS ADS/1 from 2022 to 2025. This chart illustrates how IMMUNOCORE HLDGS ADS/1's total assets have evolved over time, based on quarterly financial data. See today's stock price for IMMUNOCORE HLDGS ADS/1 for real-time trading data and today's change.
IMMUNOCORE HLDGS ADS/1 - Asset Composition Analysis
IMMUNOCORE HLDGS ADS/1 Total Assets Breakdown (December 2025)
IMMUNOCORE HLDGS ADS/1 total assets breakdown as of December 2025. IMMUNOCORE HLDGS ADS/1's total assets of €1.12 Billion consist of 93.4% current assets and 6.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 43.8% |
| Accounts Receivable | €73.98 Million | 6.9% |
| Inventory | €6.74 Million | 0.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how IMMUNOCORE HLDGS ADS/1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore IMMUNOCORE HLDGS ADS/1 (6YG) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: IMMUNOCORE HLDGS ADS/1's current assets represent 93.4% of total assets in 2025, an increase from 90.0% in 2022.
- Cash Position: Cash and equivalents constituted 43.8% of total assets in 2025, down from 76.4% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 6.9% of total assets.
IMMUNOCORE HLDGS ADS/1 Competitors by Total Assets
Key competitors of IMMUNOCORE HLDGS ADS/1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
IMMUNOCORE HLDGS ADS/1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.47 | 5.89 | 4.38 |
| Quick Ratio | 4.44 | 5.86 | 4.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €815.85 Million | €832.22 Million | €717.68 Million |
IMMUNOCORE HLDGS ADS/1 - Advanced Valuation Insights
This section examines the relationship between IMMUNOCORE HLDGS ADS/1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.28 |
| Latest Market Cap to Assets Ratio | 1.27 |
| Asset Growth Rate (YoY) | 5.7% |
| Total Assets | €1.07 Billion |
| Market Capitalization | $1.36 Billion USD |
Valuation Analysis
Above Book Valuation: The market values IMMUNOCORE HLDGS ADS/1's assets above their book value (1.27x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: IMMUNOCORE HLDGS ADS/1's assets grew by 5.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for IMMUNOCORE HLDGS ADS/1 (2022–2025)
The table below shows the annual total assets of IMMUNOCORE HLDGS ADS/1 from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €1.07 Billion ≈ $1.25 Billion |
+5.72% |
| 2024-12-31 | €1.01 Billion ≈ $1.18 Billion |
+69.10% |
| 2023-12-31 | €597.00 Million ≈ $697.96 Million |
+13.33% |
| 2022-12-31 | €526.76 Million ≈ $615.84 Million |
-- |
About IMMUNOCORE HLDGS ADS/1
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebe… Read more